These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29460236)

  • 21. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
    Regan CP; Kiss L; Stump GL; McIntyre CJ; Beshore DC; Liverton NJ; Dinsmore CJ; Lynch JJ
    J Pharmacol Exp Ther; 2008 Jan; 324(1):322-30. PubMed ID: 17967939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients.
    Deftereos S; Giannopoulos G; Kossyvakis C; Efremidis M; Panagopoulou V; Raisakis K; Kaoukis A; Karageorgiou S; Bouras G; Katsivas A; Pyrgakis V; Stefanadis C
    Am J Cardiol; 2013 Sep; 112(5):684-7. PubMed ID: 23726175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.
    Tamargo J; Caballero R; Gómez R; Delpón E
    Expert Opin Investig Drugs; 2009 Apr; 18(4):399-416. PubMed ID: 19335273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.
    Anderson JL; Gilbert EM; Alpert BL; Henthorn RW; Waldo AL; Bhandari AK; Hawkinson RW; Pritchett EL
    Circulation; 1989 Dec; 80(6):1557-70. PubMed ID: 2513143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.
    Arya A; Silberbauer J; Teichman SL; Milner P; Sulke N; Camm AJ
    Europace; 2009 Apr; 11(4):458-64. PubMed ID: 19174378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation.
    Ulimoen SR; Enger S; Carlson J; Platonov PG; Pripp AH; Abdelnoor M; Arnesen H; Gjesdal K; Tveit A
    Am J Cardiol; 2013 Jan; 111(2):225-30. PubMed ID: 23111138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of long-term ω-3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study.
    Kumar S; Sutherland F; Stevenson I; Lee JM; Garg ML; Sparks PB
    Int J Cardiol; 2013 Oct; 168(4):3812-7. PubMed ID: 23890856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The usefulness of minimal ventricular pacing and preventive AF algorithms in the treatment of PAF: the 'MinVPace' study.
    Veasey RA; Arya A; Freemantle N; Silberbauer J; Patel NR; Lloyd GW; Sulke AN
    J Interv Card Electrophysiol; 2010 Jun; 28(1):51-7. PubMed ID: 20082131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation.
    Tanaka H; Hashimoto N
    Cardiovasc Drug Rev; 2007; 25(4):342-56. PubMed ID: 18078434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
    J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.
    Scirica BM; Belardinelli L; Chaitman BR; Waks JW; Volo S; Karwatowska-Prokopczuk E; Murphy SA; Cheng ML; Braunwald E; Morrow DA
    Europace; 2015 Jan; 17(1):32-7. PubMed ID: 25210025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of atrial overdrive and ventricular rate stabilization pacing algorithms for the prevention and treatment of paroxysmal atrial fibrillation: the Pacemaker Atrial Fibrillation Suppression (PAFS) study.
    Sulke N; Silberbauer J; Boodhoo L; Freemantle N; Kamalvand K; O'Nunain S; Hildick-Smith D; Lloyd GW; Patel NR; Paul V
    Europace; 2007 Sep; 9(9):790-7. PubMed ID: 17562750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat.
    de Haan S; Greiser M; Harks E; Blaauw Y; van Hunnik A; Verheule S; Allessie M; Schotten U
    Circulation; 2006 Sep; 114(12):1234-42. PubMed ID: 16940189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiofrequency catheter ablation maintains its efficacy better than antiarrhythmic medication in patients with paroxysmal atrial fibrillation: On-treatment analysis of the randomized controlled MANTRA-PAF trial.
    Raatikainen MJ; Hakalahti A; Uusimaa P; Nielsen JC; Johannessen A; Hindricks G; Walfridsson H; Pehrson S; Englund A; Hartikainen J; Kongstad O; Mortensen LS; Hansen PS;
    Int J Cardiol; 2015 Nov; 198():108-14. PubMed ID: 26163901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel anti-arrhythmic drugs for atrial fibrillation management.
    Ehrlich JR; Nattel S; Hohnloser SH
    Curr Vasc Pharmacol; 2007 Jul; 5(3):185-95. PubMed ID: 17627562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The natural history of atrial fibrillation in patients with permanent pacemakers: is atrial fibrillation a progressive disease?
    Veasey RA; Sugihara C; Sandhu K; Dhillon G; Freemantle N; Furniss SS; Sulke AN
    J Interv Card Electrophysiol; 2015 Oct; 44(1):23-30. PubMed ID: 26139311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial).
    Darkner S; Chen X; Hansen J; Pehrson S; Johannessen A; Nielsen JB; Svendsen JH
    Eur Heart J; 2014 Dec; 35(47):3356-64. PubMed ID: 25182250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased base rate of atrial pacing for prevention of atrial fibrillation after implantation of a dual-chamber pacemaker: insights from the Atrial Overdrive Pacing Study.
    Kantharia BK; Freedman RA; Hoekenga D; Tomassoni G; Worley S; Sorrentino R; Steinhaus D; Wolkowicz JM; Syed ZA;
    Europace; 2007 Nov; 9(11):1024-30. PubMed ID: 17913697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial.
    Padeletti L; Pürerfellner H; Mont L; Tukkie R; Manolis AS; Ricci R; Inama G; Serra P; Scheffer MG; Martins V; Warman EN; Vimercati M; Grammatico A; Boriani G;
    Heart Rhythm; 2015 Aug; 12(8):1717-25. PubMed ID: 25869753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial.
    Patten M; Maas R; Bauer P; Lüderitz B; Sonntag F; Dluzniewski M; Hatala R; Opolski G; Müller HW; Meinertz T;
    Eur Heart J; 2004 Aug; 25(16):1395-404. PubMed ID: 15321697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.